Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vistagen Therapeutics Inc (VTGN)

Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,945
  • Shares Outstanding, K 39,495
  • Annual Sales, $ 490 K
  • Annual Income, $ -51,420 K
  • EBIT $ -65 M
  • EBITDA $ -66 M
  • 60-Month Beta 0.32
  • Price/Sales 42.76
  • Price/Cash Flow N/A
  • Price/Book 0.24
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.90
  • Most Recent Earnings $-0.54 on 11/13/25
  • Next Earnings Date 02/12/26 [AMC]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 326.40% (+88.25%)
  • Historical Volatility 71.43%
  • IV Percentile 89%
  • IV Rank 56.77%
  • IV High 518.95% on 11/20/25
  • IV Low 73.56% on 08/01/25
  • Expected Move (DTE 14) 0.1530 (27.17%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 449
  • Volume Avg (30-Day) 337
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 14,548
  • Open Int (30-Day) 26,122
  • Expected Range 0.4102 to 0.7162

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.50
  • Number of Estimates 2
  • High Estimate -0.49
  • Low Estimate -0.52
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5028 +12.01%
on 02/05/26
0.7670 -26.57%
on 01/07/26
-0.1584 (-21.95%)
since 01/06/26
3-Month
0.5028 +12.01%
on 02/05/26
5.1400 -89.04%
on 11/24/25
-3.4568 (-85.99%)
since 11/06/25
52-Week
0.5028 +12.01%
on 02/05/26
5.1400 -89.04%
on 11/24/25
-2.3068 (-80.38%)
since 02/06/25

Most Recent Stories

More News
VTGN Investor Alert: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline on March 16, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options

VTGN : 0.5632 (+11.52%)
Investors who lost money on Vistagen Therapeutics, Inc.(VTGN) should contact The Gross Law Firm about pending Class Action - VTGN

NEW YORK , Feb. 5, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of  Vistagen Therapeutics, Inc. (NASDAQ: VTGN).

VTGN : 0.5632 (+11.52%)
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN

LOS ANGELES , Feb. 5, 2026 /PRNewswire/ --  The DJS Law Group  reminds investors of a class action lawsuit against  Vistagen Therapeutics, Inc. ("Vistagen " or "the Company") (NASDAQ: VTGN...

VTGN : 0.5632 (+11.52%)
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Feb. 5, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics,...

VTGN : 0.5632 (+11.52%)
VTGN CLASS ACTION ALERT: Robbins LLP Urges Vistagen Therapeutics, Inc. Stockholders to Reach Out for Information About the Securities Class Action Lawsuit

SAN DIEGO , Feb. 4, 2026 /PRNewswire/ -- Robbins LLP  reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc....

VTGN : 0.5632 (+11.52%)
March 16, 2026 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTGN

NEW YORK , Feb. 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN) of a class action securities lawsuit....

VTGN : 0.5632 (+11.52%)
VTGN INVESTOR ALERT -- LEVI & KORSINSKY, LLP ANNOUNCES CLASS ACTION OVER ALLEGED MISLEADING STATEMENTS ABOUT CLINICAL TRIAL PROGRESS

VTGN INVESTOR ALERT — March 16, 2026 DEADLINE

VTGN : 0.5632 (+11.52%)
Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates...

VTGN : 0.5632 (+11.52%)
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , Feb. 2, 2026 /PRNewswire/ --

VTGN : 0.5632 (+11.52%)
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Feb. 2, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics,...

VTGN : 0.5632 (+11.52%)

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Key Turning Points

3rd Resistance Point 0.6469
2nd Resistance Point 0.6063
1st Resistance Point 0.5848
Last Price 0.5632
1st Support Level 0.5227
2nd Support Level 0.4821
3rd Support Level 0.4606

See More

52-Week High 5.1400
Fibonacci 61.8% 3.3686
Fibonacci 50% 2.8214
Fibonacci 38.2% 2.2742
Last Price 0.5632
52-Week Low 0.5028

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar